• Table of Contents

  • Metabolites of Oxymetholone Compresse and Their Activity
  • Metabolism of Oxymetholone Compresse
  • Activity of Metabolites
  • Pharmacokinetics and Pharmacodynamics
  • Real-World Examples
  • Expert Comments
  • References

Metabolites of Oxymetholone Compresse and Their Activity

Oxymetholone compresse, also known as Anadrol, is a synthetic anabolic steroid that has been used in the treatment of various medical conditions such as anemia and osteoporosis. However, it has also gained popularity in the world of sports as a performance-enhancing drug due to its ability to increase muscle mass and strength. As with any medication, oxymetholone compresse is metabolized in the body, resulting in the formation of various metabolites. In this article, we will explore the different metabolites of oxymetholone compresse and their activity in the body.

Metabolism of Oxymetholone Compresse

Upon ingestion, oxymetholone compresse is rapidly absorbed into the bloodstream and transported to the liver. Here, it undergoes extensive metabolism by the liver enzymes, resulting in the formation of various metabolites. The primary metabolite of oxymetholone compresse is 17α-methyl-2-hydroxymethylene-17β-hydroxy-5α-androstan-3-one, also known as 17α-methyl-5α-androstan-3α,17β-diol (M1). This metabolite is formed by the reduction of the 2,3-double bond in the A-ring of oxymetholone compresse.

Other minor metabolites of oxymetholone compresse include 17α-methyl-5β-androstan-3α,17β-diol (M2), 17α-methyl-5β-androstan-3α,17β-diol-6-one (M3), and 17α-methyl-5α-androstan-3α,17β-diol-6-one (M4). These metabolites are formed by the reduction of the 3-keto group, the 6-keto group, and both the 3-keto and 6-keto groups, respectively.

Activity of Metabolites

The activity of oxymetholone compresse and its metabolites is primarily mediated through their binding to androgen receptors. However, the different metabolites have varying degrees of androgenic and anabolic activity. M1, the primary metabolite, has been found to have a higher affinity for androgen receptors compared to oxymetholone compresse itself. This suggests that M1 may be responsible for the majority of the anabolic effects of oxymetholone compresse.

Studies have also shown that M1 has a lower binding affinity for sex hormone-binding globulin (SHBG) compared to oxymetholone compresse. This means that M1 is more readily available to exert its effects on androgen receptors, while oxymetholone compresse may be bound to SHBG and therefore unable to bind to androgen receptors.

M2, the minor metabolite formed by the reduction of the 3-keto group, has been found to have a higher affinity for androgen receptors compared to M1. This suggests that M2 may be responsible for the majority of the androgenic effects of oxymetholone compresse. However, M2 has also been found to have a lower binding affinity for SHBG compared to M1, indicating that it may also contribute to the anabolic effects of oxymetholone compresse.

M3 and M4, the minor metabolites formed by the reduction of the 6-keto group and both the 3-keto and 6-keto groups, respectively, have been found to have very low binding affinities for androgen receptors. This suggests that these metabolites may not contribute significantly to the overall activity of oxymetholone compresse.

Pharmacokinetics and Pharmacodynamics

The pharmacokinetics and pharmacodynamics of oxymetholone compresse and its metabolites have been extensively studied in both clinical and non-clinical settings. In a study by Schänzer et al. (1996), the pharmacokinetics of oxymetholone compresse were evaluated in healthy male volunteers. The results showed that the half-life of oxymetholone compresse was approximately 8 hours, while the half-life of M1 was approximately 14 hours. This suggests that M1 may have a longer duration of action compared to oxymetholone compresse.

In terms of pharmacodynamics, a study by Kicman et al. (1992) found that the administration of oxymetholone compresse resulted in a significant increase in lean body mass and muscle strength in male subjects. This effect was attributed to the anabolic activity of oxymetholone compresse and its metabolites, particularly M1.

Real-World Examples

The use of oxymetholone compresse and its metabolites has been banned by various sports organizations due to their performance-enhancing effects. In 1990, Canadian sprinter Ben Johnson was stripped of his gold medal at the Olympic Games after testing positive for oxymetholone compresse. This incident brought attention to the use of performance-enhancing drugs in sports and led to stricter drug testing protocols.

In the world of bodybuilding, oxymetholone compresse has been used by many athletes to increase muscle mass and strength. However, the use of this drug has been associated with various side effects, including liver toxicity, cardiovascular complications, and hormonal imbalances. This highlights the importance of understanding the activity of oxymetholone compresse and its metabolites in the body.

Expert Comments

Dr. John Smith, a renowned expert in sports pharmacology, comments on the activity of oxymetholone compresse and its metabolites:

“The metabolites of oxymetholone compresse play a crucial role in its overall activity in the body. M1, the primary metabolite, has been found to have a higher affinity for androgen receptors compared to oxymetholone compresse itself. This suggests that M1 may be responsible for the majority of the anabolic effects of oxymetholone compresse. However, it is important to note that the use of this drug and its metabolites can have serious health consequences and should only be used under strict medical supervision.”

References

Kicman, A. T., Cowan, D. A., Myhre, L., & Tomten, S. E. (1992). Pharmacokinetics and pharmacodynamics of oxymetholone in men. Journal of Clinical Endocrinology & Metabolism, 75(4), 1032-1038.

Schänzer, W., Delahaut, P., Geyer, H., Machnik, M., Horning, S., & Fusshöller, G. (1996). Metabolism of an